Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ACM Research Inc (ACMR) vs Adaptive Biotechnologies Corp (ADPT) Price & Performance

ACM Research IncTrade
Adaptive Biotechnologies CorpTrade

Price performance (Past 24H)

Key statistics

ACM Research Inc vs Adaptive Biotechnologies Corp — how do they compare? ACM Research Inc trades at $81.89 (market cap $5.57B), while Adaptive Biotechnologies Corp trades at $25.11 (market cap $4.04B). The key difference: ACM Research Inc is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, ACM Research Inc nearer its low. Which is the better fit depends on your goals.

ACMRADPT
Market Cap
$5.57B$4.04B
Sector
TechnologyHealth
52-Week High
$126.89$25.45
52-Week Low
$24.93$12.30
Enterprise Value
$4.48B$4.10B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ACM Research Inc

ACMR trades at $83.03, up 4.56% in the last session, with a neutral technical signal and bearish moving averages. Recent Q2 2026 earnings beat estimates with EPS of $0.61 versus $0.42 expected, and revenue grew 36% year-over-year to $292.9 million. The company raised its 2026 revenue guidance amid strong order growth of 105% in the first half, driven by new products like the Ultra C Tahoe wet processing platform expansion announced on August 7, 2026.

Outlook is positive with 80% analyst buy ratings and a consensus price target of $127.50, implying 54% upside. Risks include high valuation with a P/E of 37.7 and reliance on semiconductor cycle demand. Net cash flow improved to $538 million in 2026 from $355 million in 2025, supporting growth initiatives.

Adaptive Biotechnologies Corp

ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.

Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.

Returns comparison

Trailing returns across standard periods

About ACM Research Inc

ACM Research develops and manufactures semiconductor process equipment, specializing in wafer cleaning and electroplating solutions. Its tools are used by global chipmakers to improve productivity and yield for logic and memory chips.

Read more on ACMR

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT